FRI0372 Pharmacokinetics and immunogenicity of pegloticase (PL) infused every 3 weeks to treat refractory gout (RG), including in organ transplant recipients (TR)
Publication
, Conference
Hershfield, MS; Ganson, NJ; Kelly, SJ; Scarlett, EL; Jaggers, DA; Sundy, JS
Published in: Annals of the Rheumatic Diseases
June 2013
Duke Scholars
Published In
Annals of the Rheumatic Diseases
DOI
EISSN
1468-2060
ISSN
0003-4967
Publication Date
June 2013
Volume
71
Issue
Suppl 3
Start / End Page
440.1 / 440
Publisher
BMJ
Related Subject Headings
- Arthritis & Rheumatology
- 3204 Immunology
- 3202 Clinical sciences
- 1117 Public Health and Health Services
- 1107 Immunology
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Hershfield, M. S., Ganson, N. J., Kelly, S. J., Scarlett, E. L., Jaggers, D. A., & Sundy, J. S. (2013). FRI0372 Pharmacokinetics and immunogenicity of pegloticase (PL) infused every 3 weeks to treat refractory gout (RG), including in organ transplant recipients (TR). In Annals of the Rheumatic Diseases (Vol. 71, pp. 440.1-440). BMJ. https://doi.org/10.1136/annrheumdis-2012-eular.2829
Hershfield, M. S., N. J. Ganson, S. J. Kelly, E. L. Scarlett, D. A. Jaggers, and J. S. Sundy. “FRI0372 Pharmacokinetics and immunogenicity of pegloticase (PL) infused every 3 weeks to treat refractory gout (RG), including in organ transplant recipients (TR).” In Annals of the Rheumatic Diseases, 71:440.1-440. BMJ, 2013. https://doi.org/10.1136/annrheumdis-2012-eular.2829.
Hershfield MS, Ganson NJ, Kelly SJ, Scarlett EL, Jaggers DA, Sundy JS. FRI0372 Pharmacokinetics and immunogenicity of pegloticase (PL) infused every 3 weeks to treat refractory gout (RG), including in organ transplant recipients (TR). In: Annals of the Rheumatic Diseases. BMJ; 2013. p. 440.1-440.
Hershfield, M. S., et al. “FRI0372 Pharmacokinetics and immunogenicity of pegloticase (PL) infused every 3 weeks to treat refractory gout (RG), including in organ transplant recipients (TR).” Annals of the Rheumatic Diseases, vol. 71, no. Suppl 3, BMJ, 2013, pp. 440.1-440. Crossref, doi:10.1136/annrheumdis-2012-eular.2829.
Hershfield MS, Ganson NJ, Kelly SJ, Scarlett EL, Jaggers DA, Sundy JS. FRI0372 Pharmacokinetics and immunogenicity of pegloticase (PL) infused every 3 weeks to treat refractory gout (RG), including in organ transplant recipients (TR). Annals of the Rheumatic Diseases. BMJ; 2013. p. 440.1-440.
Published In
Annals of the Rheumatic Diseases
DOI
EISSN
1468-2060
ISSN
0003-4967
Publication Date
June 2013
Volume
71
Issue
Suppl 3
Start / End Page
440.1 / 440
Publisher
BMJ
Related Subject Headings
- Arthritis & Rheumatology
- 3204 Immunology
- 3202 Clinical sciences
- 1117 Public Health and Health Services
- 1107 Immunology
- 1103 Clinical Sciences